Drug-induced myopathies

Current Opinion in Neurology

Volumn 21, Issue 5, 2008, Pages 590-595

  Klopstock, Thomas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antiretroviral therapy; Coenzyme Q; Myotoxicity; Pharmacogenomics; Statin

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CERIVASTATIN; CIMETIDINE; COTRIMOXAZOLE; CYCLOSPORIN; DIAZEPAM; DIDANOSINE; ERYTHROMYCIN; FLUOXETINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LAMIVUDINE; LOCAL ANESTHETIC AGENT; PENICILLIN DERIVATIVE; PLACEBO; PROTEINASE INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TACROLIMUS; UBIQUINONE; UNINDEXED DRUG; VERAPAMIL; WARFARIN; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DIPLOPIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATTY LIVER; FOOD DRUG INTERACTION; GENETIC RISK; GRAPEFRUIT JUICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LACTIC ACIDOSIS; LOW DRUG DOSE; MITOCHONDRIAL MYOPATHY; MORBIDITY; MUSCLE CONTRACTURE; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NICOLAU SYNDROME; NONHUMAN; PANCREATITIS; PHARMACOGENOMICS; PROTEIN POLYMORPHISM; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; TENDINITIS; TENDON RUPTURE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DERMATOMYOSITIS; FLUOROQUINOLONES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCLE, SKELETAL; MUSCULAR DISEASES;

EID: 53549100162     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32830e2774     Document Type: Review

References (45)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of advene drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-1205.
2. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97:89C-94C.
3. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C.
4. Baer AN, Wortmann RL Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol 2007; 19:67-73.
5. Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007; 107:433-443.
6. García-Rodríguez LA, Gonzalez EM, Wallander MA, Johansson S. The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008 [Epub ahead of print]. This study found no safety differences between rosuvastatin and other statins.
7. Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006; 210:94-102.
8. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A 1990; 87:8931-8934.
9. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49:2231-2237. This is a thorough and comprehensive review on the role of CoQ in statinassociated myopathy.
10. Schaefer WH, Lawrence JW, Loughlin AF, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 2004; 194:10-23.
11. Päivä H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78:60-68.
12. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statinrelated myopathy. Arch Neural 2005; 62:1709-1712.
13. **] are the first controlled clinical trials on the effect of CoQ supplementation on statin-induced myopathy. The authors found a significant 40% decrease in pain severity and pain interference with daily activities.
14. **], the authors found no significant effects with regard to myalgia or statin tolerance. Both trials are underpowered and underline the need for a large randomized trial on this issue.
15. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 2005; 15:415-421.
16. Wilke RA, Lin DW, Roden DM, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6:904-916. A comprehensive review on genetic risk factors for statin-induced myopathy and other ADRs, which discusses future challenges in pharmacogenetics.
17. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34:153-162.
18. Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007; 6:7. One of the very few genetic association studies in drug-induced myopathies to date. The finding of an association between statin myopathy and polymorphisms in the CoQ biosynthesis gene COQ2 appears, however, preliminary because of methodological limitations of this study.
19. Thomas JE, Lee N, Thompson PD. Statins provoking MELAS syndrome. A case report. Eur Neurol 2007; 57:232-235.
20. Giacomini KM, Krauss RM, Roden DM, et al. When good drugs go bad. Nature 2007; 446:975-977. This article stresses the need for a global research consortium to tackle the problem of identifying individual genetic risk factors for ADRs.
21. Baker SK, Samjoo IA. A neuromuscular approach to statin-related myotoxicity. Can J Neurol Sci 2008; 35:8-21. This review presents a management algorithm for statin-induced myopathy together with three instructive case reports.
22. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-422.
23. Miller KD, Cameron M, Wood LV, et al. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 2000; 133:192-196.
24. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811-820.
25. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol 2007; 3:583-598. This review emphasizes that prevention of antiretroviral drug interactions requires thorough knowledge of CYP function and regulation by healthcare providers.
26. van der Lee M, Sankatsing R, Schippers E, et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infeoted patients. Antivir Ther 2007; 12:1127-1132.
27. Louthrenoo W. Rheumatic manifestations of human immunodeficiency virus infection. Curr Opin Rheumatol 2008; 20:92-99. This review on rheumatic manifestations in patients with HIV infection including immune reconstitution inflammatory syndrome is useful for neurologists who care for HIV patients.
28. Calza L, Manfredi R, Colangeli V, et al. Polymyositis associated with HIV infection during immune restoration induced by highly active antiretroviral therapy. Clin Exp Rheumatol 2004; 22:651-652.
29. Magro CM, Schaefer JT, Waldman J, et al. Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis. J Cutan Pathol 2008; 35:74-81. This is not only a case report, but also provides a comprehensive review on druginduced dermatomyositis and its possible mechanisms.
30. Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007; 21:17-24. This review covers rheumatologic adverse effects of statins that may also be encountered by the neurologist.
31. Riley G. Tendinopathy - from basic science to treatment. Nat Clin Pract Rheumatol 2008; 4:82-89.
32. Ng WF, Naughton M. Fluoroquinolone-associated tendinopathy: a case report. J Med Case Reports 2007; 1:55.
33. Corrao G, Zambon A, Bertu L, et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf 2006; 29:889-896.
34. Hsiao SH, Chang CM, Tsao CJ, et al. Acute rhabdomyolysis associated with ofloxacin/levofloxacin therapy. Ann Pharmacother 2005; 39:146-149.
35. Guis S, Jouglard J, Kozak-Ribbens G, et al. Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment. J Rheumatol 2001; 28:1405-1406.
36. Petitjeans F, Nadaud J, Perez JP, et al. A case of rhabdomyolysis with fatal outcome after a treatment with levofloxacin. Eur J Clin Pharmacol 2003; 59:779-780.
37. Hogan Q, Dotson R, Erickson S, et al. Local anesthetic myotoxicity: a case and review. Anesthesiology 1994; 80:942-947.
38. Gómez-Arnau Jl, Yangüela J, González A, et al. Anaesthesia-related diplopia after cataract surgery. Br J Anaesth 2003; 90:189-193.
39. Dupont M, Taylor G, Devys JM. Diplopia complicating peribulbar anesthesia for cataract surgery and early use of MRI (French). Ann Fr Anesth Reanim 2007; 26:927-930.
40. Han SK, Kim JH, Hwang JM. Persistent diplopia after retrobulbar anesthesia. J Cataract Refract Surg 2004; 30:1248-1253.
41. Scott AB, Alexander DE, Miller JM. Bupivacaine injection of eye muscles to treat strabismus. Br J Ophthalmol 2007; 91:146-148. This study describes the therapeutic use of bupivacaine myotoxicity and attracts attention to a topic rarely addressed by neurologists.
42. Burnei G, Neagoe P, Margineanu BA, et al. Treatment of severe iatrogenic quadriceps retraction in children. J Pediatr Orthop B 2004; 13:254-258.
43. Babhulkar SS. Triceps contracture caused by injections. A report of 11 cases. J Bone Joint Surg Br 1985; 67:94-96.
44. Chen HC, Huang TF, Chou PH, Chen TH. Deltoid contracture: a case with multiple muscle contractures. Arch Orthop Trauma Surg 2007 [Epub ahead of print]. It is just a case report, but worth reading as it attracts attention to a topic rarely addressed by neurologists.
45. Senel E, Ada S, Güleç AT, Caǧlar B. Nicolau syndrome aggravated by cold application after i.m. diclofenac. J Dermatol 2008; 35:18-20. Another case report that attracts attention to a topic rarely addressed by neurologists.